Promiscuity of the AlloHLA-A2 Restricted T Cell Repertoire Hampers the Generation of Minor Histocompatibility Antigen-specific Cytotoxic T Cells across HLA Barriers

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 2, 2007, Pages 151-163

  Oosten, Liesbeth E M ^a   Blokland, Els ^a   Kester, Michel G D ^a   Falkenburg, J H Frederik ^a   van Halteren, Astrid G S ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alloreac; Antigen recognition; Cytotoxic T cells; Immunotherapy; Stem cell transplantation

Indexed keywords

CYTOKINE; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; TETRAMER;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BINDING AFFINITY; BLOOD DONOR; CANCER RELAPSE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPARA; NORMAL HUMAN; PROGENY; PROTEIN TARGETING; SEX DIFFERENCE; T LYMPHOCYTE;

DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846294032     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.025     Document Type: Article

References (55)

1. Armitage J.O. Bone marrow transplantation. N Engl J Med 330 (1994) 827-838
2. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320 (1989) 197-204
3. Ottinger H., Grosse-Wilde M., Schmitz A., and Grosse-Wilde H. Immunogenetic marrow donor search for 1012 patients: a retrospective analysis of strategies, outcome and costs. Bone Marrow Transplant 14 suppl 4 (1994) S34-S38
4. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
5. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (1999) 1755-1759
6. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95 (2000) 3996-4003
7. Ash R.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 7 (1991) 443-452
8. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
9. Champlin R. T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother 2 (1993) 27-42
10. Kolb H.J., and Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 9 (1997) 139-145
11. Lewalle P., Delforge A., Aoun M., et al. Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management. Blood Cells Mol Dis 33 (2004) 256-260
12. Gao L., Bellantuono I., Elsasser A., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 (2000) 2198-2203
13. Mutis T., Blokland E., Kester M., Schrama E., and Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 100 (2002) 547-552
14. Savage P., Gao L., Vento K., et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (2004) 4613-4615
15. Dutoit V., Guillaume P., Romero P., Cerottini J.C., and Valmori D. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A* 0201- donor: exploring tumor antigen allorestricted recognition. Cancer Immun 2 (2002) 7
16. Sadovnikova E., Parovichnikova E.N., Savchenko V.G., Zabotina T., and Stauss H.J. The CD68 protein as a potential target for leukaemia-reactive CTL. Leukemia 16 (2002) 2019-2026
17. Moris A., Teichgraber V., Gauthier L., Buhring H.J., and Rammensee H.-G. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 166 (2001) 4818-4821
18. Amrolia P.J., Reid S.D., Gao L., et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 101 (2003) 1007-1014
19. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
20. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., and Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93 (1999) 2336-2341
21. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 8 (1996) 75-81
22. de Bueger M., Bakker A., Van Rood J.J., van der Woude F., and Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 149 (1992) 1788-1794
23. van der Harst D., Goulmy E., Falkenburg J.H.F., et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83 (1994) 1060-1066
24. Falkenburg J.H.F., Goselink H.M., van der Harst D., et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 174 (1991) 27-33
25. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100 (2003) 2742-2747
26. Hambach L., Nijmeijer B.A., Aghai Z., et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 20 (2006) 371-374
27. den Haan J.M., Meadows L.M., Wang W., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279 (1998) 1054-1057
28. den Haan J.M., Sherman N.E., Blokland E., et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268 (1995) 1476-1480
29. Wang W., Meadows L.R., den Haan J.M., et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269 (1995) 1588-1590
30. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 (1996) 7569-7579
31. Mutis T., Gillespie G., Schrama E., Falkenburg J.H.F., Moss P., and Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 5 (1999) 839-842
32. Gillespie G., Mutis T., Schrama E., et al. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. Hematol J 1 (2000) 403-410
33. de Bueger M., Verreck F., Blokland E., et al. Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. Eur J Immunol 23 (1993) 614-618
34. Oosten L.E.M., Blokland E., van Halteren A.G.S., et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 104 (2004) 224-226
35. Mommaas B., Kamp J., Drijfhout J.W., et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 169 (2002) 3131-3136
36. Verdijk R.M., Kloosterman A., Pool J., et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 103 (2004) 1961-1964
37. van Els C.A., D'Amaro J., Pool J., et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 35 (1992) 161-165
38. Burrows S.R., Khanna R., Silins S.L., and Moss D.J. The influence of antiviral T-cell responses on the alloreactive repertoire. Immunol Today 20 (1999) 203-207
39. Wucherpfennig K.W. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 40 (2004) 1009-1017
40. Maverakis E., van den Elzen P., and Sercarz E.E. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 16 (2001) 201-209
41. Wilson D.B., Wilson D.H., Schroder K., et al. Specificity and degeneracy of T cells. Mol Immunol 40 (2004) 1047-1055
42. Heemskerk M.H., de Paus R.A., Lurvink E.G., et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA 98 (2001) 6806-6811
43. Matzinger P., and Bevan M.J. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens?. Cell Immunol 29 (1977) 1-5
44. Lindahl K.F., and Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med 145 (1977) 508-522
45. Rotzschke O., Falk K., Faath S., and Rammensee H.-G. On the nature of peptides involved in T cell alloreactivity. J Exp Med 174 (1991) 1059-1071
46. Chattopadhyay S., Theobald M., Biggs J., and Sherman L.A. Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity. J Exp Med 179 (1994) 213-219
47. Elliott T.J., and Eisen H.N. Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc Natl Acad Sci USA 87 (1990) 5213-5217
48. Smith P.A., Brunmark A., Jackson M.R., and Potter T.A. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med 185 (1997) 1023-1033
49. Alexander-Miller M.A., Burke K., Koszinowski U.H., Hansen T.H., and Connolly J.M. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol 151 (1993) 1-10
50. Tallquist M.D., Yun T.J., and Pease L.R. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J Exp Med 184 (1996) 1017-1026
51. Obst R., Munz C., Stevanovic S., and Rammensee H.-G. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. Eur J Immunol 28 (1998) 2432-2443
52. Sadovnikova E., and Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 93 (1996) 13114-13118
53. Wang W., Man S., Gulden P.H., Hunt D.F., and Engelhard V.H. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides. J Immunol 160 (1998) 1091-1097
54. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
55. Ogg G.S., Jin X., Bonhoeffer S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106